Pappalysin-2 (Recombinant)
- Expression system
- HEK293
- Cat. #
- REC-Pappalysin2
In stock
- SKU
- REC-Pappalysin2
Target Overview
Pappalysin-2 (PAPPA2; UniProt Q9BXP8) is a secreted metzincin-family zinc metalloproteinase encoded by a 1,791-amino-acid open reading frame. Its defining enzymatic activity is selective proteolytic cleavage of insulin-like growth factor binding protein-5 (IGFBP-5) at the Ser163–Lys164 bond, with limited secondary activity toward IGFBP-3. By cleaving these binding proteins, PAPPA2 modulates the bioavailability of IGF ligands in the local extracellular environment, making it a key regulatory node in IGF signalling cascades. This recombinant is produced in HEK293 mammalian cells, a system that supports the glycosylation and disulfide-bond formation required for the correctly folded, secreted form of the enzyme. HEK293 expression is particularly important for a large, disulfide-rich metalloproteinase such as PAPPA2, where prokaryotic or insect-cell systems often yield inactive or misfolded material. Researchers use this recombinant in several well-defined assay formats. In substrate-cleavage assays, recombinant PAPPA2 is incubated with purified IGFBP-5 or IGFBP-3, and cleavage products are resolved by SDS-PAGE or quantified by ELISA. In inhibitor screening programmes, the recombinant serves as the enzyme source for IC50 determination against candidate small molecules or biologics that block metalloproteinase activity. The protein is also used as a positive-control antigen for antibody validation — researchers working with immunoassay or imaging workflows can pair this recombinant with Triple Point Biologics' matched antibody (SKU: RP-Pappalysin2), which has been validated for Western blot, to confirm signal specificity and estimate molecular weight under native or denaturing conditions. Additionally, the recombinant supports surface plasmon resonance and biolayer interferometry experiments characterising PAPPA2 interactions with IGFBP substrates, IGF ligands, or candidate inhibitor compounds.
Background
Applications
- IGFBP-5 substrate cleavage assay (Ser163–Lys164 site; products resolved by SDS-PAGE or quantified by ELISA)
- IGFBP-3 limited proteolysis assay to compare substrate selectivity relative to IGFBP-5
- Small-molecule metalloproteinase inhibitor IC50 determination in fluorescence- or gel-based formats
- Antibody validation positive control for Western blot using matched TPB antibody RP-Pappalysin2
- Surface plasmon resonance or biolayer interferometry characterisation of PAPPA2–IGFBP-5 binding kinetics
- IGF bioavailability reconstitution assay in cell-based models (PAPPA2-mediated release of IGF from IGFBP-5 complex)
- Recombinant enzyme source for mass spectrometry–based identification of PAPPA2 cleavage site(s) in candidate substrates
References
- Zhang N et al. Potentials of BMSCs for regulating osteogenic-vascular-neural-lymphatic coupling in bone regeneration. Biomed Eng Online. 2026. doi:10.1186/s12938-026-01594-7. PMID: 42298623.
- Fernández-Arjona MDM et al. Sex-specific hormonal rescue of bone growth in PAPPA2-deficient mice: a role for cannabinoid receptors and STAT3. Bone Joint Res. 2026. doi:10.1302/2046-3758.155.BJR-2025-0563.R1. PMID: 42125896.
- Wang G et al. PAPPA2 c.392G>C Heterozygous Mutation Associates Primary Open-Angle Glaucoma in a Chinese Family. Hum Mutat. 2026. doi:10.1155/humu/5591097. PMID: 41993134.
- Buhl LF et al. IGF-PAPP-A-stanniocalcin axis and androgenic anabolic steroid use in men and women. Eur J Endocrinol. 2026. doi:10.1093/ejendo/lvag037. PMID: 41715938.
- Chen W et al. Insulin-like growth factor signaling regulates zebrafish lymphatic-vessel development. Cell Rep. 2026. doi:10.1016/j.celrep.2026.116971. PMID: 41691624.
Additional Specifications
| Storage Buffer | 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol |
|---|---|
| Endotoxin Level | <0.1 EU/µg by LAL |
| Purity (%) | >90% by SDS-PAGE |
| Expression System | HEK293 |
| Subcellular Localization | Subcellular localization not yet annotated |
Frequently Asked Questions
What is the expected molecular weight of recombinant Pappalysin-2 on SDS-PAGE and Western blot?
The PAPPA2 open reading frame encodes 1,791 amino acids, giving a predicted unglycosylated molecular weight of approximately 200 kDa. Because this recombinant is expressed in HEK293 cells, N-linked glycosylation adds significant mass; expect the band to migrate at approximately 220–250 kDa under denaturing, reducing SDS-PAGE conditions. Batch-to-batch glycan heterogeneity can produce a diffuse or doublet band in this range — this is normal and does not indicate degradation. Purity is confirmed at >90% by Coomassie-stained SDS-PAGE prior to release.
What processing or isoform state is this recombinant Pappalysin-2 — proform or mature enzyme?
This recombinant is produced and secreted as the processed, mature form of PAPPA2 from HEK293 cells. The signal peptide is cleaved co-translationally, and the product represents the catalytically active secreted enzyme rather than an unprocessed proform. PAPPA2 does not require a separate prodomain removal step in vitro before use in cleavage assays. If your experiment requires distinguishing proform versus mature PAPPA2 by Western blot, the matched rabbit polyclonal antibody (RP-Pappalysin2) is a reliable detection reagent for both forms.
What substrate does recombinant Pappalysin-2 cleave and at which bond?
PAPPA2's primary enzymatic activity is proteolytic cleavage of insulin-like growth factor binding protein-5 (IGFBP-5) at the Ser163–Lys164 peptide bond. This cleavage liberates IGF ligands from the IGFBP-5 complex, increasing local IGF bioavailability. PAPPA2 shows limited secondary activity toward IGFBP-3 but does not efficiently cleave IGFBP-1, -2, -4, or -6. For substrate-cleavage assays, recombinant IGFBP-5 is the appropriate primary substrate. Cleavage can be confirmed by the disappearance of intact IGFBP-5 (~30 kDa) and appearance of the characteristic N- and C-terminal fragments on reducing SDS-PAGE.
What buffer conditions are recommended for Pappalysin-2 activity assays in vitro?
The protein is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, and 5 mM CaCl₂ — the CaCl₂ is essential for metalloproteinase stability and is included in this formulation specifically for PAPPA2. For activity assays, dilute into a compatible reaction buffer maintaining pH 7.4–7.5 and at least 1–2 mM CaCl₂. Avoid chelating agents (EDTA, EGTA) as these strip the catalytic zinc ion and abolish activity. DTT at concentrations above 1 mM can also reduce activity; if a reducing environment is required, use TCEP at ≤0.5 mM instead.
What starting concentration of recombinant Pappalysin-2 should I use in an IGFBP-5 cleavage assay?
A practical starting point is 50–200 nM recombinant PAPPA2 incubated with 500 nM–1 µM recombinant IGFBP-5 at 37°C for 2–16 hours, depending on the sensitivity of your readout. For gel-based cleavage assays, a 4-hour incubation at 100 nM PAPPA2 with 500 nM IGFBP-5 typically produces clearly visible fragment bands. For ELISA-based quantification of released IGF-I or residual intact IGFBP-5, titrate PAPPA2 from 10–500 nM to establish a linear dose-response range appropriate for your inhibitor or substrate concentration studies.
Can I use recombinant Pappalysin-2 as a positive control for Western blot with the RP-Pappalysin2 antibody?
Yes — this is one of the primary validated uses of this recombinant. The matched rabbit polyclonal antibody (RP-Pappalysin2; /anti-pappalysin-2-rabbit-polyclonal-antibody) is raised and validated in the same laboratory, ensuring epitope-antigen compatibility. Load 10–50 ng of recombinant PAPPA2 per lane alongside your cell lysate or conditioned medium samples. The recombinant will produce a clean band at ~220–250 kDa, serving as both a size reference and a sensitivity benchmark for the antibody dilution you are optimizing. This pairing is particularly useful when validating RP-Pappalysin2 for detection of endogenous PAPPA2 in placental or serum samples.
How much recombinant Pappalysin-2 should I load for Western blot positive control and at what antibody dilution?
Load 25–50 ng per lane for a standard positive control lane using RP-Pappalysin2. At this loading, the antibody performs reliably at 1:500–1:2,000 dilution with HRP-conjugated anti-rabbit secondary antibody and standard ECL detection. If you are working with conditioned medium where endogenous PAPPA2 is at low concentrations, include a 10 ng recombinant lane to verify antibody sensitivity at the lower end of your detection range. Avoid loading >100 ng, as signal saturation can obscure the glycosylation-related band diffuseness and may bleed into adjacent sample lanes.
How should I store and handle recombinant Pappalysin-2 to preserve enzymatic activity after arrival?
Upon receipt, briefly centrifuge the vial, then aliquot into single-use volumes appropriate for your assay scale — freeze immediately at -20°C. Repeated freeze-thaw cycles progressively reduce metalloproteinase activity; even two additional cycles can result in measurable loss of IGFBP-5 cleavage efficiency. For short-term use (up to 1 week), the protein is stable at 4°C in its supplied buffer. Do not dilute working stocks in water; maintain buffer ionic strength and the 5 mM CaCl₂ in any dilution buffer. Shelf life is 12 months from date of manufacture when stored continuously at -20°C.
Validation imagery coming soon
Western blot validation figures for REC-Pappalysin2 will be published here as they are produced in-house.
If you would like to see existing validation data for this antibody before publication, request a sample copy.